SCHEMBL14480909

SCHEMBL14480909

CCC(=O)N1CCN(c2nc3c(C)c(F)ccc3cc2[C@H](C)Nc2ncnc3cccnc23)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 4/20 0.37
PIK3R2 O00459 1/20 0.36
PARP1 P09874 1/20 0.35
CHRM1 P11229 2/20 0.34
CD274 Q9NZQ7 1/20 0.34
AKT1 P31749 1/20 0.34
AKT2 P31751 1/20 0.34
AKT3 Q9Y243 1/20 0.34
GPR6 P46095 1/20 0.34
NPC1 O15118 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
RAB9A P51151 1/20 0.33
OPRK1 P41145 2/20 0.33
LRRK2 Q5S007 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
CKS1B P61024 1/20 0.33
SKP1 P63208 1/20 0.33
SKP2 Q13309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14480910 1.00 PIK3CD (0.37) PIK3CDPIK3R2PARP1CHRM1CD274
SCHEMBL15899853 0.92 PIK3CD (0.39) PIK3CDPIK3R2PARP1CHRM1CD274
SCHEMBL14480930 0.92 PIK3CD (0.39) PIK3CDPIK3R2CD274AKT1AKT2
SCHEMBL14480929 0.92 PIK3CD (0.39) PIK3CDPIK3R2CD274AKT1AKT2
SCHEMBL15900051 0.91 PIK3CD (0.38) PIK3CDPIK3R2PARP1CD274AKT1
SCHEMBL14481337 0.91 PIK3CD (0.38) PIK3CDPIK3R2PARP1CD274AKT1
SCHEMBL14481197 0.90 SOS1 (0.40) PIK3CDPIK3R2CD274MAPT
SCHEMBL14480691 0.89 CYP3A4 (0.38) PIK3CDPIK3R2CD274AKT1AKT2
SCHEMBL14480692 0.89 CYP3A4 (0.38) PIK3CDPIK3R2CD274AKT1AKT2
Formic Acid SCHEMBL14481352 0.89 PIK3CD (0.38) PIK3CDPIK3R2PARP1CHRM1CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2499129-B1 QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-07-30 EP claimed
US-8653105-B2 Quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2014-02-18 US claimed
US-20130012517-A1 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2013-01-10 US claimed
EP-2499129-B1 QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-07-30 EP disclosed
US-8653105-B2 Quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2014-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012517-A1 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors PDXK, MAP2K2, PDPK1 PIK3CD 13/4885PIK3R2 106/4885PARP1 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.